Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

NCT06465069 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06465069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06465069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Recruiting
Start date
July 1, 2024
Completion date
May 31, 2027
Enrollment
420 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, bladder cancer, cervical cancer, esophageal cancer, head and neck squamous cell carcinoma, metastatic solid tumor, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, recurrent solid tumor, renal pelvis cancer, triple negative breast cancer, urinary bladder neoplasm